Skin Involvement is seen in nearly 76 per cent of Systemic lupus erythematosus (SLE) patients, but bullous lesion however accounts for less than one per cent of cutaneous manifestation of lupus erythematosus. A 21-year-old female presented with fever, polyarthalgia and vesicobullous skin lesion and acute renal failure. Clinico-pathological evaluation imparted that she was having bullous systemic lupus erythematosus (BSLE) with lupus nephritis. She was put on rituximab after initial resuscitation. She responded dramatically with resolution of skin lesion and recovery from acute renal failure. She was followed up for one year without complication with stable disease course.
What is known about this subject?
Bullous Systemic Lupus Erythematosus has been reported very infrequently in literature. It is a skin manifestation of SLE.
What new information is offered in this case study?
Response to Rituximab a CD20 monoclonal antibody has not been reported adequately in literature which has been shown here.
What are the implications for research, policy, or practice?
Patient with SLE with extensive bullous lesion can be managed with Rituximab as an alternative to Dapsone. SLE nephropathy too can be controlled by Rituximab therapy.
Background
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease. It can virtually involve all organ systems. Skin Involvement is seen in nearly 76 per cent of all lupus patients, 1 most common are malar rash, discoid rash and photo sensitivity. Bullous lesion, however accounts for less than one per cent of cutaneous manifestation of lupus.1 Bullous systemic lupus erythematosus (BSLE) is a distinctive entity characterised by histological appearance of sub epidermal bulla with deposition of pan immuno reactants and circulating antibody against type VII collagen (NC1 domain) and occasionally other antigens like laminin 5, laminin 6, and bullous pemphigoid antigen (BP230). 2 BSLE frequently parallels internal organ involvement.3 In this case report we have reported a case of bullous systemic lupus erythematosus (BSLE) who presented with an organ threatened condition in the form of rapidly progressive glomerulonephritis (RPGN).
Case details
A 21-year-old, newly married female without any living issue and foetal loss, resident of eastern India presented to IPGME&R hospital with presenting complaints of low to moderate grade intermittent fever (with occasional high rise of temperature) for last six months, pain, redness and swelling of both large and small joints (mostly additive) for last six months. Also rapidly progressive painful vesicobullous skin lesion involving both sun exposed and nonexposed areas i. We diagnosed our patient as Bullous systemic lupus erythematosus (BSLE) with ISN/RPS class IV lupus nephritis with active lesion presenting with rapidly progressive glomerulonephritis (RPGN).
Initially patient was managed with Methylprednisolone pulse therapy 1gm once a day IV for three days followed by oral Prednisolone with Hydroxychloroquine and systemic broad spectrum antibiotics from day one. Dapsone was started with 100mg BD for bullous lesion but she was intolerant to Dapsone. Eventually her renal biopsy report came on day 10 th of admission; with suggestion of active lupus nephritis, she was put on Rituximab 375mg/square meter body surface area. Later we received her skin biopsy report only to corroborate our clinical impression and forming our final diagnosis.
One month after completion of two doses of Rituximab, her renal impairment and skin lesions improved significantly. Biochemical assessment showed normalisation of creatinine value (1.2mg/dl) with a creatinine clearance of 60ml/min and reduction of proteinuria. In her subsequent visit after six months of 4 th dose of Rituximab, proteinuria reduced further and renal recovery was nearly complete with creatinine clearance of 74ml/min without any further complication.
Discussion
BSLE accounts for less than one per cent of skin manifestations, 1 generally affects young adult females and involves both sun-exposed and non-exposed areas. Because of the particularly clinical and histological presentation of BSLE, Camisa and Sharma proposed diagnostic criteria for BSLE; these include i) A diagnosis of SLE based on the ACR criteria; ii) Vesicles and bullae mainly located on sunexposed areas; iii) The histopathology is characterised by sub-epidermal bullae with micro abscesses of neutrophils in the dermal papillae, similar to those found in dermatitis herpetiformis; and iv) Deposition of IgG, IgM, or both and often IgA in the basement membrane zone. 2 Rituximab which is a chimeric monoclonal antibody that reacts with CD20, an antigen that is present on immature, naive, and memory B cells but not on mature plasma cells, has been approved in the treatment of SLE with good efficacy and safety. 3 In this case report we have used Rituximab as an immuno modulator in a complicated life threatening situation of target organ damage. We have experienced a dramatic response in terms of skin lesions and renal recovery in our patient. Hydroxychloroquine and tapering dose of Prednisolone was prescribed to his patient and even after three successive follow up one month and six months apart no more bullous lesion was observed in this patient and her renal recovery was satisfactory.
Till now, there is only one case report showing improvement of skin lesion with Rituximab as a treatment of BSLE, but unlike this case Mycophenolate mofetil was used alongside. 4 In this case a satisfactory response solely due to Rituximab has been observed even in an advanced life threatening nephropathy situation. This is obvious that potential role of Rituximab as an immuno modulator cannot be left aside.
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Conclusion
Rituximab can be given as an alternative to Dapsone in bullous lesion associated with SLE and as an immuno modulator in active lupus nephritis with satisfactory renal outcome. 
